A Sophomore's Plan to End Needles

Let's Start a Company

In the fall of 2003, Elizabeth Holmes was a 19-year-old sophomore at Stanford.[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

She sat down in the office of her chemical engineering professor, Channing Robertson, and said: "Let's start a company."[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

Notice how small the scene is: one student, one professor, one office, which is how Theranos began.

With his blessing, she started one. A semester later, she dropped out to run it full-time.[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

Picture a tiny startup, not a big firm. Her parents even let her use money saved for her education.[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

This lesson follows what she promised, and what her early device could really do.

A Fear Becomes a Mission

Holmes said needles had always bothered her. She told Fortune in 2014 that "the concept of sticking a needle into you and sucking your blood out" disturbed her.[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

Her goal was bold: replace the arm needle with painless, near-instant blood testing.

The company's first name was Real-Time Cures. The later name, Theranos, blends "therapy" and "diagnosis."[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

In 2009 she said a finger prick could show whether a drug "works, whether it's safe and whether they have the right dose."[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

From Patch to Finger Prick

Her first patent application described a wearable patch. It would "radio the doctor what is going on in your blood in real time."[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

Then the idea shrank.

The first real device, the TSPU, tested a few drops of finger-prick blood for drug-company trials. The SEC says it "was capable of performing only a few tests."[[2]](https://www.sec.gov/litigation/complaints/2018/comp-pr2018-41-theranos-holmes.pdf)

So Theranos did not start with a working, do-everything machine that later broke. The early device was real but narrow.

A Star Professor Says Yes

Robertson was then dean of Stanford's engineering school. He backed Holmes and served for years as a company director.[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

He later said: "I realized that I could have just as well been looking into the eyes of a Steve Jobs or a Bill Gates."[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

Praise like that from a respected scientist carries real weight with investors.

One boundary: dropping out is not a warning sign by itself. Many legitimate founders did it. The later problem was the gap between claims and evidence.

The Story Was the Pitch

Her origin story was more than background. The SEC says her investor pitch cited technology "spurred by her own fear of needles."[[2]](https://www.sec.gov/litigation/complaints/2018/comp-pr2018-41-theranos-holmes.pdf)

The pitch mixed three parts: a relatable fear, a bold technical promise, and a respected scientist's backing.

Together, they made doubt feel like doubting the mission itself.

A moving founder story can stand in for proof. Investors may feel they understand a product when they have only heard why it matters.

Claims Grew Faster Than Proof

The company began in fall 2003. Her last arm blood draw came in 2007, required for key-person insurance.[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

By 2009 she claimed a finger prick could check whether a drug works and is safe.[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

Early backers included Draper Fisher Jurvetson and Larry Ellison. By June 2014, Theranos had raised more than $400 million.[[1]](https://fortune.com/2014/06/12/theranos-blood-holmes/)

Money and promises kept growing. The evidence did not keep pace.

Judging Claims Against the Record

Now you can test a claim the way many investors did not.

First, separate the story from the evidence. A fear of needles explains motive. It proves nothing about a machine.

Second, ask what the device actually did. The patch was an idea in a patent application, and the TSPU could run only a few tests.[[2]](https://www.sec.gov/litigation/complaints/2018/comp-pr2018-41-theranos-holmes.pdf)

Third, notice who is vouching. A famous backer is a reason to look closer at the data.

Elizabeth Holmes began her company in 2003 while she was a Stanford sophomore.

• True
• False

Answer: True

This is true. Holmes was 19 and a Stanford sophomore when she asked Professor Channing Robertson to help start a company.

The product idea moved from a _____ that would report blood data in real time to the _____, which tested finger-prick blood for _____ but could perform only _____.

Answer: The product idea moved from a wearable patch that would report blood data in real time to the TSPU, which tested finger-prick blood for drug-company trials but could perform only a few tests.

The idea began as a wearable patch, then became the TSPU. The TSPU was used for drug-company trials, but its capabilities were narrow: it could perform only a few tests.

What did the early TSPU actually do?

• It tested a few drops of finger-prick blood for drug-company trials.
• It continuously monitored blood through a wearable patch.
• It performed every blood test needed in a clinic.
• It only existed as a drawing and was never built.

Answer: It tested a few drops of finger-prick blood for drug-company trials.

The TSPU was a real but limited device. It tested a few drops of finger-prick blood for drug-company trials and could perform only a few tests. It was not a fully capable machine that later stopped working.